- May 31, 2022
How engineers and drug developers are working to change childhood cancer’s deadly calculus
A non-profit organization merges engineering and biology to accelerate drug development for childhood cancers. Read more: https://www.nature.com/articles/d41586-022-01513-5
- May 30, 2022
Young Adult Blood Cancer Survivors Face increased Risk Of Death For Decades After Treatment
Young adults who have survived leukemia have higher mortality rates than people in the general population, even for decades after their treatment, according to a new study. Read more: https://www.forbes.com/sites/victoriaforster/2022/05/27/young-adult-blood-cancer-survivors-face-increased-risk-of-death-for-decades-after-treatment/?sh=38406eb1339e
- May 24, 2022
FDA Approves Vidaza for Rare Pediatric Blood Cancer
The Food and Drug Administration (FDA) approved Vidaza (azacytidine) for the treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia, a rare blood cancer where certain types of white blood cells do not mature normally. Read more: https://www.curetoday.com/view/fda-approves-vidaza-for-rare-pediatric-blood-cancer
- May 18, 2022
New molecular subset of pediatric liver cancer identified
New research from Baylor College of Medicine and Texas Children’s Cancer Center characterizes a new molecular type of high-risk pediatric liver cancer. The study, published in the Journal of Hepatology, showed that these tumors have better outcomes when patients were treated by transplantation, rather than by chemotherapy and surgery alone. Read more: https://www.bcm.edu/news/new-molecular-subset-of-pediatric-liver-cancer-identified
- May 11, 2022
Frozen testicular tissue still viable after two decades
The results may have important implications for treatment of boys with cancer, for whom chemotherapy may be preceded by harvesting and freezing of testicular tissue for eventual reimplantation. Read more: https://www.eurekalert.org/news-releases/951471
- May 10, 2022
Study identifies potential target for treating childhood blood cancer
Scientists have pinpointed a possible new target for treating patients with the blood cancer juvenile myelomonocytic leukaemia (JMML), according to a new study. Read more: https://www.sciencedaily.com/releases/2022/05/220510102932.htm
- May 9, 2022
RAI Treatment in DTC Survivors Associated With Increased Risk of Other Cancers
Increased risks of several solid tumors found to be associated with radioactive iodine treatment for patients with childhood and young-adulthood differentiated thyroid cancer. Read more: https://www.targetedonc.com/view/rai-treatment-in-dtc-survivors-associated-with-increased-risk-of-other-cancers
- May 5, 2022
AYA cancer survivors at higher risk for death due to second primary cancers
Death due to a second primary cancer occurred nearly twice as often among adolescent and young adult cancer survivors compared with the general population, according to study results published in Journal of the National Cancer Institute. Read more: https://www.healio.com/news/hematology-oncology/20220504/aya-cancer-survivors-at-higher-risk-for-death-due-to-second-primary-cancers
- May 4, 2022
Immunotherapy for kids: An option for childhood liver cancer?
This rare and aggressive form of childhood liver cancer shares enough similarities with its adult counterpart to make it a good disease for which to study immunotherapy treatments. Read more: https://answers.childrenshospital.org/liver-immunotherapy/
- May 3, 2022
Biological pathways found that drive genomic changes and bone metastasis in Ewing Sarcoma
In studies using mice grafted with human Ewing sarcoma tissue, researchers from Georgetown University Medical Center and colleagues have identified a biological pathway that is activated when tissue is starved of oxygen due to rapid growth of a tumor, thereby allowing cancer cells to make genetic changes so they can metastasize to the bone and thrive even when exposed to chemotherapy. Read more: https://medicalxpress.com/news/2022-04-biological-pathways-genomic-bone-meta